Senior Physician Speaker Series
Curated and hosted by Sam Yared, MD
Topic: Advances in Structural Heart Disease: From Bench to Bedside Guest Speaker: Ravi Sharma, MD
At the March meeting of the Senior Physicians Committee, Dr. Sam Yared, chair, introduced interventional cardiologist Dr. Ravi Sharma, who offered a broad look at how structural heart disease treatment has evolved over the past decade, and where the field is headed next. His message to colleagues was clear: cardiovascular care is entering an era defined by minimally invasive therapies, rapid device innovation and increasingly collaborative, multidisciplinary care.
Structural heart disease encompasses a wide range of conditions involving the heart’ s valves, chambers and supporting structures. Historically, treatment for many of these disorders required openheart surgery. Today, however, advances in catheter-based therapies and imaging technologies are dramatically expanding treatment options for patients who might once have been considered too high risk for intervention.
Dr. Sharma began by reflecting on the remarkable pace of change within interventional cardiology. The field has evolved rapidly since the first balloon angioplasty procedures were performed in the late 1970s. Over the following decades, coronary stenting transformed the management of coronary artery disease. Today, fourth-generation drug-eluting stents offer improved durability and dramatically reduced rates of restenosis compared with earlier devices.
“ These technologies have continued to evolve,” Dr. Sharma explained, noting that the next frontier includes bioresorbable scaffolds and further refinements in stent design aimed at optimizing long-term outcomes.
But while coronary intervention remains central to cardiology, structural heart disease therapies have emerged as one of the most transformative areas in cardiovascular medicine. Over the past decade, transcatheter procedures have moved from experimental therapies to standard treatment options for many patients.
One of the most prominent examples is transcatheter aortic valve replacement( TAVR). Initially developed for patients who were not candidates for surgical valve replacement, TAVR has rapidly expanded to include patients at intermediate and even low surgical risk. The procedure allows physicians to replace a diseased aortic valve using a catheter inserted through a peripheral artery( often the femoral artery) avoiding the need for open-heart surgery.
The result is shorter hospital stays, faster recovery and access to life-saving treatment for patients who might otherwise go untreated.“ TAVR has fundamentally changed the landscape of aortic
34 LOUISVILLE MEDICINE